trending Market Intelligence /marketintelligence/en/news-insights/trending/hoohjj5hfv8nb7bn0ll5xa2 content esgSubNav
In This List

TransEnterix gets US FDA clearance for expanded use of surgery system

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


TransEnterix gets US FDA clearance for expanded use of surgery system

The U.S. Food and Drug Administration granted a 510(k) clearance for expanded indications of TransEnterix Inc.'s Senhance Surgical System.

The regulatory approval was granted for two surgeries namely, laparoscopic inguinal hernia, a tear in the abdominal muscle, and laparoscopic cholecystectomy, the removal of the gallbladder.

Following this approval, Senhance can be used for some of the most common abdominal surgeries, including procedures in general surgery and gynecology.

President and CEO Todd Pope said that the indication expansion doubles the addressable market for Senhance in the U.S.